UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
|
|
- Clementine Cannon
- 5 years ago
- Views:
Transcription
1 UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System
2 UF Decisions, May 07 Class FY05 rank, total $ Implementation (decision date implementation date) On UF Uniform Formulary NF BCF / ECF Antilipidemics II 24 Jul Nov 07 (120 days) Multiple meds (fenofibrate except Antara, Tricor) gemfibrozil cholestyramine colestipol Micronized and nanocrystallized fenofibrate (Antara, Tricor) colesevelam (Welchol) prescription omega-3 fatty acids (Lovaza, formerly Omacor) BCF gemfibrozil IDD-P fenofibrate (Triglide) May 07 5-ARIs ARBs 24 Jul Oct 07 (90 days) 24 Jul Nov 07 (120 days) PPIs 24 Jul Oct 07 (90 days) finasteride dutasteride (Avodart) BCF finasteride candesartan (Atacand) losartan (Cozaar) telmisartan (Micardis) (& HCTZ combos) omeprazole esomeprazole (Nexium) Irbesartan (Avapro) eprosartan (Teveten) olmesartan (Benicar) valsartan (Diovan) (& HCTZ combos) lansoprazole (Prevacid) omeprazole/sodium bicarb (Zegerid) pantoprazole (Protonix) rabeprazole (Aciphex) Auto PA omeprazole or esomeprazole prior to non-formulary PPIs BCF telmisartan (Micardis & Micardis HCT) BCF generic omeprazole esomeprazole 2
3 Class Implementation (decision date implementation date) On UF UF Decisions, Feb 07 Uniform Formulary NF BCF / ECF Feb 07 Nov 06 Aug 06 Ophthalmic Glaucoma Agents Newer Sedative Hypnotics (SED-1s) ADHD / Narcolepsy Agents 2 May 07 1 Aug 07 (90 days) 2 May 07 1 Aug 07 (90 days) multiple meds eszopiclone (Lunesta) zolpidem IR travoprost (Travatan, Travatan Z); timolol hemihydrate (Betimol); timolol maleate (Istalol); brinzolamide (Azopt) ramelteon (Rozerem) zaleplon (Sonata) zolpidem ER (Ambien CR) Zolpidem IR prior to Ambien CR, Lunesta, Rozerem, Sonata 17 Jan Apr 07 (90 days) LIP1s 23 Oct 06 1 Feb 07 (90 days) atomoxetine, methylphenidate IR & ER, mixed amphetamine salts, IR & ER (Adderall XR), dextroamphetamine, methamphetamine modafinil, Na oxybate atorvastatin (Lipitor); ezetimibe/simvastatin (Vytorin); ezetimibe (Zetia); fluvastatin IR & ER (Lescol, Lescol XL); lovastatin IR & ER (Altoprev); niacin ER (Niaspan); niacin IR; niacin ER/lovastatin (Advicor) pravastatin; simvastatin dexmethylphenidate IR and ER (Focalin, Focalin XR) methylphenidate patch (Daytrana) rosuvastatin (Crestor) atorvastatin/ amlodipine (Caduet) latanoprost (Xalatan); timolol maleate soln 0.25% and 0.5% soln & gel-forming soln; brimonidine 0.2% & 0.15%; pilocarpine zolpidem IR (Ambien) methylphenidate IR & ER (specifically Concerta) amphetamine salts, ER (Adderall XR) simvastatin; pravastatin; niacin ER (Niaspan); ezetimibe/ simvastatin (Vytorin)
4 Definitions 30 day equivalent (30d equiv) Automated prior authorization (Auto PA) UF VARR 18 month look back Arbitrary for 6 months prior to statin decision 4
5 300, , , , ,000 50,000 0 LIP 1 ADHD NF/3 rd Tier 30d equiv All POS ARB PPI LIP 2 NSH OGA 5ARI 5 6/30/06 7/31/06 8/31/06 9/30/06 10/31/06 11/30/06 12/31/06 1/31/07 2/28/07 3/31/07 4/30/07 5/31/07 6/30/07 7/31/07 8/31/07 9/30/07 10/31/07 11/30/07 Signing date Implementation date
6 140, , ,000 80,000 60,000 40,000 LIP 1 20,000 0 NF/3 rd Tier 30 day Rxs Retail PPI ARB LIP 2 NSH 5ARI OGA ADHD 6 12/31/05 1/31/06 2/28/06 3/31/06 4/30/06 5/31/06 6/30/06 7/31/06 8/31/06 9/30/06 10/31/06 11/30/06 12/31/06 1/31/07 2/28/07 3/31/07 4/30/07 5/31/07 6/30/07 7/31/07 8/31/07 9/30/07 10/31/07 11/30/07 Signing date Implementation date
7 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 LIP 1 0 NF/3 rd Tier 30 day Rxs MTFs ARB PPI LIP 2 NSH 5 ARI ADHD OGA 7 12/31/05 1/31/06 2/28/06 3/31/06 4/30/06 5/31/06 6/30/06 7/31/06 8/31/06 9/30/06 10/31/06 11/30/06 12/31/06 1/31/07 2/28/07 3/31/07 4/30/07 5/31/07 6/30/07 7/31/07 8/31/07 9/30/07 10/31/07 11/30/07 Signing date Implementation date
8 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 LIP 1 ADHD NF/3 rd Tier 30 day Rxs Mail Order ARBs PPI LIP 2 NSH 5ARI OGA 8 6/30/06 7/31/06 8/31/06 9/30/06 10/31/06 11/30/06 12/31/06 1/31/07 2/28/07 3/31/07 4/30/07 5/31/07 6/30/07 7/31/07 8/31/07 9/30/07 10/31/07 11/30/07 0 Signing date Implementation date
9 400, , , , , , ,000 50,000 0 NF/3 rd Tier 30d Rxs By Point of Service Retail Mail Order MTF 9 6/30/06 7/31/06 8/31/06 9/30/06 10/31/06 11/30/06 12/31/06 1/31/07 2/28/07 3/31/07 4/30/07 5/31/07 6/30/07 7/31/07 8/31/07 9/30/07 10/31/07 11/30/07
10 35% 30% 25% 20% 15% 10% 5% 0% Retail % NF/3 rd Tier By POS 30d Rxs Mail Order Overall -26% MTF 10
11 $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $- Cost Per Day by POS Retail Overall -14% Mail Order MTF 11
12 What affects utilization and cost Formulary decisions Drugs going generic Implementation of Auto PA Reality: Combination of all of the above Example classes Statins Newer Sedative Hypnotics PPIs ADHD 12
13 700, ,000 Statin Utilization All POS 30 day Equivalents ZOCOR & Generics 500, , ,000 LIPITOR 200,000 VYTORIN ZETIA 100,000 CRESTOR - 13
14 160, , , ,000 80,000 60,000 40,000 20,000 - Statin Utilization Retail 30 day Equivalents LIPITOR ZOCOR & Generics VYTORIN ZETIA CRESTOR 14
15 Statin Utilization MTF 30 day Equivalents 450, ,000 ZOCOR & Generics 350, , , , , ,000 LIPITOR VYTORIN ZETIA 50,000-15
16 120,000 Statin Utilization Mail Order 30 day Equivalents 100,000 ZOCOR & Generics 80,000 60,000 LIPITOR 40,000 VYTORIN 20,000 CRESTOR ZETIA - 16
17 $4.00 Statins Ave Cost/Day All POS $3.50 CADUET $3.00 $ Oct: signing date 1 Feb Implementation Date LIPITOR $2.00 $1.50 $1.00 CRESTOR VYTORIN ZETIA Class Average -33% $0.50 PRAVACHOL & Generics $- ZOCOR & Generics 17
18 30d E q uiv in m illions Statin 30d Equiv trend - All POS All drugs % 18 M ay-06 Ju n -06 Ju l-06 Aug -06 Sep -06 N o v-06 D ec-06 Jan -07 M ay-07 Ju n -07 Ju l-07 Aug -07 Sep -07 N ov-07
19 100,000 90,000 80,000 Newer Sedative Hypnotic Utilization All POS 30 day Equivalents AMBIEN & Generics May 1: signing date Aug 1: Auto PA initiated 70,000 60,000 50,000 40,000 30,000 AMBIEN CR 20,000 10,000 ROZEREM LUNESTA SONATA - 19
20 Newer Sedative Hypnotic Utilization Retail 30 day Equivalents 60,000 May 1: signing date Aug 1: Auto PA initiated 50,000 AMBIEN & Generics 40,000 30,000 20,000 AMBIEN CR LUNESTA 10,000 - ROZEREM SONATA 20
21 Newer Sedative Hypnotic Utilization MTF 30 day Equivalents 40,000 35,000 May 1: signing date Aug 1: Auto PA initiated 30,000 AMBIEN & Generics 25,000 20,000 15,000 10,000 5,000 - SONATA AMBIEN CR ROZEREM LUNESTA 21
22 10,000 9,000 8,000 7,000 Newer Sedative Hypnotic Utilization Mail Order 30 day Equivalents AMBIEN & Generics May 1: signing date Aug 1: Auto PA initiated 6,000 5,000 4,000 3,000 AMBIEN CR LUNESTA 2,000 1,000 ROZEREM SONATA - 22
23 Newer Sedative Hypnotic Ave. Cost/Day All POS $3.50 $3.00 LUNESTA May 1: signing date Aug 1: Auto PA initiated AMBIEN CR $2.50 SONATA $2.00 ROZEREM $1.50 $1.00 AMBIEN & Generics Class Average -47% $0.50 $- 23
24 New Sedative Hypnotic 30d Equiv trend - All POS All drugs 170, , , , , % 120, , , M ay-06 Ju l -06 O ct-06 N o v-06 D ec-06 Jan -07 Mar -07 Ap r -07 M ay-07 Ju l -07 O ct-07 N o v-07
25 300, , , , ,000 50,000 PPI Utilization All POS 30 day Equivalents Jul 24: Signing Date ACIPHEX OMEPRAZOLE PREVACID PROTONIX 24 Oct : Auto PA initiated NEXIUM - ZEGERID 25
26 100,000 90,000 PPI Utilization Retail 30 day Equivalents Jul 24: Signing Date 24 Oct : Auto PA initiated 80,000 70,000 60,000 50,000 40,000 30,000 PROTONIX PREVACID NEXIUM OMEPRAZOLE ACIPHEX 20,000 10,000 - ZEGERID 26
27 200, , , , , ,000 80,000 60,000 40,000 20,000 PPI Utilization MTF 30 day Equivalents PREVACID ZEGERID ACIPHEX Jul 24: Signing Date PROTONIX 24 Oct : Auto PA initiated OMEP NEXIUM - 27
28 60,000 PPI Utilization Mail Order 30 day Equivalents 50,000 Jul 24: Signing Date 24 Oct : Auto PA initiated NEXIUM 40,000 30,000 20,000 10,000 PREVACID ACIPHEX PROTONIX OMEP - ZEGERID 28
29 PPI Ave Cost/Day All POS $4.00 $3.50 Jul 24: Signing Date 24 Oct : Auto PA initiated $3.00 ZEGERID $2.50 $2.00 $1.50 PREVACID Class Average ACIPHEX PROTONIX NEXIUM $1.00 $0.50 OMEPRAZOLE $- 29
30 800, , , , , , , , , , ,000 PPI 30d Equiv trend - All POS All drugs +11% 30 M ay-06 Ju l-06 Sep -06 O ct-06 D ec-06 Jan -07 M ay-07 Ju l-07 Sep -07 O ct-07
31 ADHD Utilization All POS 30 day Equivalents 40,000 35,000 30,000 CONCERTA 25,000 20,000 15,000 10,000 5,000 ADDERALL XR Jan 7: Signing Date STRATTERA Apr 17 : Implementation date - 31
32 ADHD Ave Cost/Day All POS $3.50 $3.00 STRATTERA FOCALIN XR Jan 7: Signing Date Apr 17 : Implementation date $2.50 ADDERALL XR $2.00 CONCERTA $1.50 Class Average +8% $1.00 $0.50 $- METHYLPHENIDATE ER METHYLPHENIDATE IR ADDERALL & Generics 32
33 110,000 ADHD 30d Equiv trend - All POS All drugs 100,000 90, % 80,000 70,000 33
34 Caveats Limited number of classes 18 month time frame Conservative estimates VARR savings not included Conservative estimates 34
35 Significant savings with aggressive formulary management Growth in utilization of each class Conclusions Formulary management techniques don t appear to be inhibiting use of benefit Step therapy is guiding utilization to most desired drug product Medical requirements and class makeup may prevent significant savings 35
36 Questions? 36
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
More informationTRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationCost Effectiveness Recommendations For Kentucky Retirement Systems MTM Plan 2011
Medication Tier 2 options Tier 1 options Nexium- Tier 3 Aciphex Lansoprazole Omeprazole Pantoprazole Crestor- Tier 3 Lipitor Simvastatin Vytorin- Tier 3 Atacand- Tier 3 Avapro Benicar Cozaar Micardis Tevetan
More informationBLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationRxBlue 2010 ST Criteria
RxBlue 2010 ST Criteria ANTIDEPRESSANTS - SARAFEM... 10 FLUOXETINE HCL... 10 SARAFEM... 10 SELFEMRA... 10 ANTIDEPRESSANTS- SSRI, SNRI... 11 CELEXA... 11 CITALOPRAM... 11 CYMBALTA... 11 EFFEXOR XR... 11
More informationUniform Formulary Decisions 9 January 2014
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 9 January 2014 Purpose: The purpose of this handout is to provide the BAP members with a reference document for the clinical effective presentation
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationADHD STIMULANTS-S(SHC)
Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug
More informationSTEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationCerner Bulletin Providers Issued: October 2, 2014
Alert Warfarin Ordered without INR CPOE, Nursing and Pharmacy 10/13/14 S B A R Prescribers currently do NOT get a warning if warfarin is actively ordered and there has not been an INR result in the past
More informationDoctor discussion guide:
Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.
More informationDoctor discussion guide:
Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 July 2008
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 July 2008 PURE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationGenerics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INTERIM MEETING
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INTERIM MEETING Addendum December 17, 2013 I. UNIFORM FORMULARY (UF) DRUG CLASS REVIEWS A. Anti-Lipidemic-ls (LIP-ls) Background-New
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More information2013 Step Therapy (ST) Criteria
2013 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationANTICHOLINERGIC BRONCHODILATORS ANTICHOLINERGIC BETA-AGONIST COMBO'S CORTICOSTEROID / BRONCHODILATOR COMBO'S NASAL STEROIDS LEUKOTRIENE MODIFIERS
1 of 5 ALLERGY / ASTHMA THERAPIES ANTIHISTAMINES, MINIMALLY SEDATING cetirizine fexofenadine loratadine ANTIHISTAMINE/DECONGESTANT COMBINATIONS cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine
More informationMARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa
MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa PHARMACY POLICY & PROCEDURES Policy Number: 3.26 Subject: Purpose: Policy: Formulary Management through Establishing Guidelines, Policies or Therapeutic
More informationPDF created with pdffactory trial version
We are using more prescription drugs than ever before to manage health conditions and prevent problems. And those drugs are more expensive than ever before. In 2003, prescription drug costs in the United
More informationII. UF CLASS REVIEWS SHORT-ACTING BETA AGONISTS (SABAs)
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationPassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC p1 Medication Review, Cardiovascular Drugs Click Here for Glossary Index! Click Here to Print Topic Help File
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationMTF Quarterly Webcast December 9, 2010
TMA Fort Sam Houston, TX MTF Quarterly Webcast December 9, 2010 LTC Stacia Spridgen Director, 1 Introduction Greetings from the PEC Purpose of the Quarterly MTF Webcast DCO Ground Rules Type questions
More informationPharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action
More informationSmithRx Standard Formulary Step Therapy List
SmithRx Standard Formulary Step Therapy List Revised: January 27, 2017 The following medications require prior use of at least one other medication for coverage. Please note that any plan-specific customizations
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end
More informationValue-Based Drug List for ABCs of Diabetes
Effective January 1, 2019 Value-Based Drug List for ABCs of Diabetes PCPS provides a Value-Based Benefit Design (VBD) to qualified participants in the ABCs of Diabetes. This means you will have lower out-of-pocket
More informationAdmission History 10/15/14
NURSING DOCUMENTATION OPTIMIZATION Admission History 10/15/14 Admission Assessments have been optimized and renamed as Admission Information... The forms are customized for Pre-Surgical/Procedural and
More informationStep Therapy Program Precision Formulary
Step Therapy Program Precision Formulary Physician Guidelines Failure of previous steps in the Step Therapy Program: For most therapies, Magellan Rx Management will review the most recent 180 days of claim
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationInformation in these slides is used with permission from St. Mary s Cardiac Rehab
Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationAGGRENOX. Products Affected. Details. GRP B2 Last Updated: 09/01/2018. Aggrenox
GRP B2 Last Updated: 09/01/2018 AGGRENOX Aggrenox A documented trial of one month of formulary generic aspirin/dipyridamole capsules. NR_0009_3742 09/2014 Formulary ID: 18066: version 15 1 ANTICONVULSANTS
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationDRUG CLASSIFICATION. Prevention of Cardiovascular Disease
Generic Preventive Care/ Safe Harbor Drug Program List Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition.
More informationHigh-Cost Drug Exclusions
Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationCHOLESTEROL REDUCING MEDICATIONS. Five Main Categories. 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor
Page 1 of 5 PHA-GEN-002-2004 CHOLESTEROL REDUCING MEDICATIONS Five Main Categories 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor Statins Also called HMG-CoA reductase inhibitors
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Step Therapy Individual and Family Plan Table of Contents Coverage Policy... 1 General Background... 5 References... 5 Effective Date... 3/15/2018 Next Review
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationMedications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy
Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Competency for CDE Exam 3.1.A Oral Medications for Type 2 Diabetes
More informationAvoid paying too much for your prescriptions
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions 2017 Aetna Rx Step Program Medicine List Avoid paying too much for your prescriptions It s important to try to
More information2019 Step Therapy (ST) Criteria
2019 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationConversion of crestor to lipitor
Conversion of crestor to lipitor Apr 25, 2018. Atorvastatin (Lipitor ): 10 mg, Fluvastatin (Lescol ): 80 mg, Rosuvastatin. Nov 16, 2011. In a head-to-head test of two popular cholesterol-lowering statin
More informationGeneric Preventive Care/ Safe Harbor Drug Program List
Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition. The Generic Preventive Care/Safe Harbor Drug Program
More informationNational Medicines Management Programme
National Medicines Management Programme Michael Barry 28 th November 2013 The Medicines Management Programme Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information
More informationAGGRENOX. Products Affected. Details. First Health Part D Value Plus (PDP) Last Updated: 10/01/2017. Aggrenox
First Health Part D Value Plus (PDP) Last Updated: 10/01/2017 AGGRENOX Aggrenox A documented trial of one month of formulary generic aspirin/dipyridamole capsules. NR_0009_3742 09/2014 Formulary ID: 18059:
More informationANGIOTENSIN RECEPTOR BLOCKERS
Step Therapy 2014 2 Tier-Alameda Last Updated: 10/10/2014 ANGIOTENSIN RECEPTOR BLOCKERS Benicar Benicar Hct Diovan Valsartan Step 1: First line therapy should be irbesartan, irbesartan/hctz, losartan,
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationAtorvastatin and upper arm pain
P ford residence southampton, ny Atorvastatin and upper arm pain Caduet (amlodipine and atorvastatin ) is used to treat high blood pressure or angina in patients with high cholesterol. Includes Caduet
More informationAdditional Standard Generics HSA Preventive Drug List Effective January 1, 2019
Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019 Employers can elect to include an additional generic HSA Preventive Drug coverage feature with your prescription benefit
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, HealthNow New York Inc. requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.
More informationDaiichi Sankyo, Inc. (DSI)
Daiichi Sankyo, Inc. (DSI) Outlook for U.S. Business for 2009 Nov. 7 th, 2007 Joseph P. Pieroni President and CEO Daiichi Sankyo, Inc. Largest Pharmaceutical markets $300 $274.4 Annual Sales (US$ billions)
More informationARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET
ARBS DIOVAN HCT 160-12.5 MG TAB, DIOVAN HCT 80-12.5 MG TABLET 30-day trial of a Step 1 drug in the previous 120 days is required. Step 1 Drugs: Losartan, Losartan/HCTZ PAGE 1 LAST UPDATED 05/2016 BILE
More informationPravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationATYPICAL ANTIPSYCHOTICS
Step Therapy CareOregon 2018 Last Updated: 07/27/2018 ATYPICAL ANTIPSYCHOTICS Fanapt Fanapt Titration Pack Paliperidone Er Vraylar The following criteria applies to members who newly start on the drug:
More informationCHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013
CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013 How to Use the Prescription Drug Program The Chicago Regional Council of Carpenters Welfare Fund has
More informationDiseases & Conditions
http://my.clevelandclinic.org Diseases & Conditions About Cholesterol-Lowering Drugs Some people have a genetic predisposition to high blood cholesterol levels. These people may need drug therapy in addition
More informationMedications for Type 2 Diabetes CDE Exam Preparation
Medications for Type 2 Diabetes CDE Exam Preparation Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Agenda Medication
More informationTHE ART OF DRUG SYNTHESIS
THE ART OF DRUG SYNTHESIS Edited by Douglas S. Johnson Jie Jack Li Pfizer Global Research and Development WILEY-INTERSCIENCE A JOHN WILEY & SONS, INC., PUBLICATION Foreword Preface Contributors xi xiii
More information> 130 > 130 (10-20% risk) <130 >160 (<10% risk) 0-1 Risk Factors <160 >160 >190
Pharmacotherapy of Dyslipidemia Disease State Definition Epidemiology Pathophysiology Clinical Presentation Polygenic LDL above 160 or TG HDL below 40-65 million quality for lifestyle changes - 36 million
More informationConnecticut Medicaid P&T Meeting Minutes June 5, 2008
Connecticut Medicaid P&T Meeting Minutes June 5, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Kenneth Marcus, MD Lester Silberman, MD Peggy Manning Memoli, Pharm D Richard
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationGuide to the Modernized Reference Drug Program
Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 8 January 2008
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 8 January 2008 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationEstimated dates are subject to change due to patent litigation, additional patents, exclusivities
Estimated dates are subject to change due to patent litigation, Estimated Dates of Possible First Time Generic/ Rx-to-OTC Market Entry Uroxatral alfuzosin extendedrelease Benign prostatic hyperplasia Anzemet
More informationResponsible Quantity Program Effective 4/1/10. Abilify oral solution
Abilify Abilify Discmelt Abilify oral solution Aciphex Actiq Page 1 of 9 750 ml 120 units Actonel 5 mg, 30 mg Actonel 35 mg 4 tabs Actonel 75 mg 2 tabs Actonel 150 mg 1 tab Actonel with Calcium Adcirca
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 U.S.C. 1074g, as implemented by 32
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
More informationIntroducing exciting new Rx benefits 2019
Introducing exciting new x benefits 2019 In 2019, the Middlesex prescription plan is aligning with best-in-class evidence-based practices. Two new tiers will be added that evaluate drugs on the basis of
More informationANTIDEPRESSANTS - BUPROPION
Step Therapy Paramount Medicare Formulary 2012 Formulary ID 12112, Version 22. CMS Approved 10-23-2012. ANTIDEPRESSANTS - BUPROPION Aplenzin may be given. Step 1 Drug(s): Budeprion Sr, Budeprion Xl, Bupropion
More informationAnnual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
More informationEvaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationThe Weekly Mortar & Pestle
The Weekly Mortar & Pestle A Publication of Walgreens Health Initiatives February 7, 2008 A publication created especially for our clients and associates, delivering up-to-date information about brand-name
More informationDate: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes
Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes 2018 Formulary-UM Changes What does this mean now, and for 2018? A number
More informationMedicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At Risk Population: Measure 33 Coronary Artery Disease (CAD-7): Angiotensin-Converting Enzyme (ACE) Inhibitor
More information